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Lifetime prevalence of anabolic-androgenic steroid use among patients in 
substance use disorder treatment in Norway 
 
Abstract 
Background 
Anabolic-androgenic steroid (AAS) use is associated with serious mental and physical health 
problems. Evidence indicates that AAS use amongst people who use psychoactive  substances is 
higher than in the general population.  
This study aims to estimate lifetime AAS use among patients in substance use disorder (SUD) 
treatment, compare characteristics of AAS and non-AAS users and identify whether AAS use was 
addressed during treatment.  
Methods 
This cross-sectional survey included 563 (142 women, 24.2%) patients in 38 SUD-treatment facilities 
in Norway. Respondents reported on AAS and substance use, and treatment experiences. 
Results 
Lifetime AAS use was reported by 156 (28.3%) SUD-patients, thereof 35.6 % of the men and 8.0% of 
the women. Lifetime AAS use was highest among men with stimulants (55.8%) as preferred 
substance, and lowest among men who preferred alcohol (14.6%). Initiation of AAS use due to 
getting thinner following substance use was reported by 44.5% of the AAS using men. AAS users 
reported more severe substance use than non-AAS users. More than half (58%)of all patients had 
not been asked about AAS use, and 42.4% of those who were asked, experienced that treatment 
providers lacked expertise about AAS.  
Conclusion 
Lifetime AAS use in this sample of SUD patients is common practice and comprise an 
underrecognized problem in SUD treatment. Given the deleterious implications to the individual and 
society that concomitant use of AAS may cause, it would be essential to raise the awareness about 
AAS use amongst SUD patients, and the level of competence among health professionals.  
 
 
 
 
 
 
Key words: Anabolic androgenic steroids, image and performance enhancing drugs, human 
enhancement drugs, substance use disorder, substances use disorder treatment, health 
services  
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1 Introduction 
Anabolic-androgenic steroids (AAS) include the male hormone testosterone and its synthetic 
derivatives 1. AAS are typically administered in supra-physiological doses over periods, 
referred to as cycles, or used continuously with constant or various dosages 2. These 
substances are extremely efficient in promoting increased muscle size and strength 3, either 
in the pursuit of an idealised body image, as a result of cultural stimuli or for some, as a 
result of body dysmorphic disorders 4-7.  
Whilst use of AAS amongst women has been identified 8-10, the majority of AAS users are 
men 11,12. Use of AAS has been associated with a range of medical and psychological side-
effects 13 including mental health disorders 14,15, reduced brain volume 16,17 and cognitive 
function 18-20, metabolic and endocrine disturbance 21-23, and cardiovascular pathology 24,25. 
AAS use is associated with use of other image and performance enhancing drugs and 
psychoactive substances use 26-28, and such a poly-drug taking repertoire is common 29-31. 
For instance, high levels of psychoactive substance use, in particular stimulants, have been 
identified in cohorts of AAS users 32,33. 
Comorbidity between use of psychoactive substances and AAS is complex and may reflect 
shared underlying brain deficits 34, genetic vulnerabilities including personality factors, 
and/or early exposure to stress or trauma. Environmental factors 35,36 such as criminality, 
incarceration and deprivation 37,38 may also be significant. A further explanation lies in the 
self-directed treatment of adverse effects of psychoactive substance use for example the 
maintenance of bodyweight and muscularity 39 or in addressing testosterone suppression 
with reduced libido or impotence 40.  
With an estimated lifetime prevalence in Norway of approximately 2-3% 41, the use of AAS 
in the general population may be considered low. However, there is considerable variation 
in estimated AAS prevalence between countries 12,42, and within specific sections of society, 
including those attending substance use disorder (SUD) programmes with opioids and 
amphetamines as their drug of choice 26,39,43. In a north American study 13% of male SUD 
treatment patients reported prior AAS use 26, whereas 27.5% of young SUD patients in a 
treatment facility in Norway had used AAS 39. These findings, from a single treatment site 
are concerning, however they may not be generalisable, illustrating the need for nationwide 
studies of SUD patients.  
Individuals with substance use disorders have much higher morbidity, live more years with 
disability and live shorter when compared with the general population 44-46. Concomitant 
use of AAS could potentially result in even higher morbidity and mortality due to adverse 
effects and pharmacological interactions. Hence, there is a need to estimate lifetime AAS 
use among patients in SUD treatment and whether history of AAS use is a subject in SUD 
treatment. Data were collected from 38 SUD treatment facilities in Norway, with treatment 
targeting different types of SUD.  
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The study aimed to: 1) estimate lifetime AAS use among patients in SUD treatment, 2) 
compare characteristics and substance use among AAS and non-AAS users, and 3) identify 
patient’s experience of interaction with health professionals regarding AAS. 
 
2 Material and methods: 
This cross-sectional survey consists of self-report data from patients in SUD treatment 
institutions/facilities in Norway. 
2.1 Setting 
SUD treatment in Norway is publicly funded, widely available, and individuals with SUD have 
treatment rights as patients . There are 103 SUD treatment institutions where 66 provide 
inpatient treatment. The in-patient treatment capacity at any given moment is 1798 beds 
and the minimum occupancy rate vary between 80-95%. In 2017, 33000 patients, where 
one third were women, received SUD treatment 47. 18500 of the patients were diagnosed 
with SUD related to illicit substances and sedatives, thereof one third in inpatient treatment 
. Inpatient SUD-treatment is directed towards complex treatment needs, such as SUD and 
co-occuring social and/or somatic and/or mental health problems. Outpatient treatment is 
provided for a range of SUDs and addictive disorders and includes opioid maintenance 
treatment. In Norway, the specialized SUD treatment system is responsible for providing 
health care to individuals with health problems related to previous or present use of AAS 
and other doping agents 48. Use and possession of AAS and other doping agents is illegal in 
Norway since the Norwegian Drug Act was amended in 2013.  
2.2 Data collection 
The management of different SUD treatment centers in Norway were contacted, informed 
about the study and asked whether they wanted to take part. 38 treatment facilities from all 
four health regions in Norway participated in the study. Data collection was mostly 
organized by the research group, and in some cases by the local treatment centers Among 
the 630 patients that were asked to participate, 516 (81.9%) filled out the questionnaire. For 
the remaining 47 participants, data are missing on how many patients that were asked and 
how many that chose not to participate in the study. Patients were informed of the study 
and inclusion criteria for those who agreed to participate were to be in active treatment for 
SUD and/or other addictive behaviors including gambling, above 18 years of age and able to 
give informed consent. 
2.3 Measures 
The questionnaire took about 30 minutes to complete, and covered the following: 
Background and health information: Gender, age, marital status and level of education was 
registered. Country of origin was categorized as either Norway, other Nordic countries 
(Sweden, Denmark, Finland, Iceland) and other. Weight and height were used to calculate 
Body Mass Index (BMI). Previous or current prescribed medication was registered; Attention 
Deficit Hyperactivity Disorder (ADHD) medications, Testosterone Replacement Therapy 
(TRT) and Opioid Maintenance Treatment (OMT) with methadone or buprenorphine.  
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Substance use: Substance use/dependence was evaluated with selected items from the 
European Addiction Severity Index (EuropASI) 49, adapted to the present study. These items 
covered different aspects of substance use behavior including age of onset of substance use 
and age of first SUD diagnose, preferred substances and substances used during a typical 
week prior to treatment. “Multiple substances” were registered if the patient listed two or 
more substances used in a normal week or answered “yes” to the question: “do you 
normally use several substances per day?”.  
AAS use: Age of first time use, compounds, and average weekly dose in milligrams was 
registered. Participants reported pattern of use as; planned or unplanned cycles, continuous 
use with variable or constant dosages, TRT and other (mainly consisting of those who had 
tried one cycle or less). Lifetime AAS use was defined as previous or present use. Time of 
AAS use was reported in years and months. If this variable was missing and the participant 
reported debut age, given cycle length and time between cycles and time since last use of 
AAS, time of AAS use was calculated. Those who reported use of one or few injections were 
registered with one month of use. 
Exercise habits: The participants were asked whether they exercised regularly, numbers of 
workouts per week and whether they  practised regular strength training.  
AAS use as a topic in SUD treatment. The participants were asked whether, during 
treatment, they had been asked about AAS use and if they perveived treatment providers to 
have knowledge about AAS. They were also asked whether they considered AAS to be an 
important subject during treatment. The study particpants were divided in four groups 
according to length of AAS use: no use, ˂ 1 year, 1-3 years, and ≥ 3 years.  
  
2.4 Ethics 
The study was approved by the data protection officer at the Oslo University Hospital 
(2016/1119). All participants received oral and written information about the study, and 
written formal consent were collected from all participants. Emphasis was placed on 
voluntary participation, confidentiality and that refrainment from participation was possible 
at any stage of the study prior to publication of data.  
2.5 Analyses and statistics 
The data were organized and handled in SPSS 25. Descriptive statistics were applied to 
generate frequencies and mean values. In order to determine statistical differences 
between AAS exposed and non-exposed participants, t-tests was used for continuous 
variables and chi-square tests for categorical data, and p-values <  0.05 were considered 
statistically significant. In analyses with missing data, valid percent was used, and numbers 
of missing presented.  
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3 Results 
3.1 Participants 
The study comprised 563 patients, thereof 414 men (74.5%) and 142 women (25.5%). The 
majority (n=453, 80.5%) of the participants were inpatients and 108 (19.2%) were 
outpatients. Norway was country of origin for the majority of the sample 93.8% (512), 
whereas 3.3% (18) were born in other Nordic countries and 2.9 % (16) orginated from other 
countries. For these measures answers were missing for 7, 2 and 17 responses respectively. 
3.2 Lifetime prevalence of AAS use 
In this sample of 563 patients in SUD treatment in Norway, 28.3 % (n=156) reported lifetime 
use of AAS, thereof 35.6 % (145) of the male and 8.0 % (11) of the female study participants. 
Among the AAS lifetime users, 30.5 % (46)  reported plans to use AAS in the future, whereas 
only 3.3 % (13) of the participants who had never used AAS  reported such plans. 
3.3 Lifetime AAS use according to preferred psychoactive substance among men 
Figure 1 illustrates the lifetime use of AAS for male SUD patients (n=406) categorized by 
their preferred psychoactive substance. Highest lifetime prevalence of AAS use was seen in 
male SUD patients listing stimulants (55.8 %) as their preferred substance and lowest among 
those reporting alcohol as preferred substance (14.6 %).  
 
Insert Figure 1 
 
3.4 Background variables and exercise habits among male illicit substance users 
Characteristics and comparisons of male SUD patients with and without lifetime AAS-use are 
shown in Table 1. Patients reporting lifetime AAS-use were younger, less educated had more 
often been prescribed medication and were more likely to exercise regularly than patients 
without AAS-experience.  
 
Insert Table 1 
 
3.5 Differences in substance use patterns between the AAS exposed and non- 
exposed male SUD patients 
 
Patients with lifetime AAS-use were younger when they initiated drug use, were diagnosed 
with SUD earlier, and had shorter time between substance use debut and SUD diagnose 
than their non-AAS exposed counterparts (Table 2). Alcohol was more often the preferred 
substance among non-AAS SUD patients, whereas stimulants were more often reported as 
preferred substance among the AAS-group. Use of multiple substances was more common 
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among patients with lifetime AAS-use, who reported using a higher number of substances 
weekly than patients with no AAS experience (3.8 vs 2.5).  
The groups also differed regarding which substances they typically used during a week, with 
AAS users being more likely to use all cathegories of illicit substances  than their non-AAS 
using counterparts who were more likely to use alcohol.  
 
Insert Table 2 
 
To further explore the differences between AAS users and their non AAS using counterparts, 
those who reported alcohol as their only illicit substance use were excluded from analyses 
(For detailed information, see the supplementary Table S1). Overall, lifetime AAS users had 
a more severe and complex substance use history and were significantly more likely to use 
heroin, other opioids, benzodiazepines, cocaine and amphetamines in a weekly basis. 
 
3.6 Pattern of AAS use among men 
Characteristics of AAS usage among men are presented in table 3. Briefly, AAS use was 
commonly initiated in the early twenties (22.8, SD 6.1, range 14-45), and length of use 
ranged from one month to 17 years. More than half reported administering doses between 
300-1000mg per week, where 2.4 different AAS typically were used concurrently. The 
majority, 64.3 % (90), reported having a substance use problem prior to their AAS initiation, 
26.4 % (37) had tried substances before AAS, 7.1 % (10) started using AAS before they 
developed a substance use problem, while three did not remember. 60.2 % (80) reported 
using AAS and psychoactive substances simultaneously, and 44.5 % (57) reported that they 
started using AAS because the use of other psychoactive substances have made them 
thinner. Only four (3.1 %) started using psychoactive substances to counteract side effects 
of AAS. 
 
Insert Table 3 
 
3.7 Pattern of AAS use among women 
Among the 142 female SUD patients, 11  reported lifetime AAS use, and one of them 
reported plans to use AAS in the future. They had a mean age of 31.6 (SD 6.5, range 22-40) 
(one missing), and the mean age of first time AAS use was 21.7 (4.8, 14-28). AAS had been 
used for an average of 15.2 months (22.5,1-72), two missing. Three reported having used 
weekly doses of 300-1000 mg, one reported above 2000 mg, while seven did not report the 
used weekly dose. 
.  
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Nine reported having had a substance use problem before their first initiation of AAS, seven 
reported concurrent AAS and substance use. Four reported that one of the reasons for 
starting to use AAS was because use of other substances had made them thinner. 
 
3.8 AAS as an Issue in SUD treatment 
Of all SUD patients, 34.4% reported that they had been asked about previous or present AAS 
use during treatment, 58.0% had not been asked while 7.6% was uncertain (8 missing). 
Whether AAS use had been an topic in treatment was not related to whether the patient 
had a history of AAS use per se, but instead to the length that AAS had been used. All groups 
of SUD patients with AAS-experince were more likely to have been asked than non-AAS 
patients (see figure 2).  
Out of the 186 SUD patients that had been asked about AAS while in treatment, 14.7 % 
experienced that their treatment providers had expertise about AAS, 42.4% experienced 
that they lacked expertise on the topic, whereas 41.3% was not sure or answered that it was 
not relevant. There were no differences between the three AAS-groups and those without 
AAS-experience regarding whether they experienced clinicians to have knowledge about 
AAS. The findings are visualized in Figure 2.  
 
Insert Figure 2 
 
4 Discussion 
This Norwegian nationwide cross-sectional study of 563 patients in SUD treatment found 
that 28.3 % reported lifetime AAS use, 35.6% of the men and 8.0% of the women. During 
SUD treatment, 58.0% of patients had not been asked about AAS use in SUD treatment, and 
only 14.7 % of those that had been asked experienced that their treatment providers had 
expertise about AAS. The findings highlights the poly substance taking nature of patients in 
SUD treatment, of which AAS forms an underecognized part. 
Early initiation of substance use and polypharmacy. AAS using SUD patients reported more 
severe substance use than non-AAS users. They were younger and reported first time 
substance use and first SUD-diagnose at an earlier age. AAS use was common among males 
who preferred to use stimulants and less common among men with alcohol as most used 
substance. Co-dependence on and displacement between psychoactive substance use and 
AAS is both complex and concerning. There is increasing evidence and focus regarding AAS 
and their propensity for dependence 14,50. Recently our research group found that 
dependent AAS-users had structural brain characteristics partly resembling what have been 
observed for other dependencies, such as thinner cortex in prefrontal regions and larger 
nucleus accumbens 51, and could point to a shared vulnerability for dependencies in general. 
Given the medical risks associated with both chronic AAS and substance use on internal 
organs or organ systems including the cardiovascular system 24,52,53, the human brain 
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16,17,20,54, kidney and liver 55,56, and the endocrine system 21,23 , the combined use of AAS and 
psychoactive substances will likely increase the risks for medical implications considerably. 
For example, use of stimulants is associated with aging of the cardiovascular system 57, 
vasospasm 58 and increased risk of myocardial infarction 59. Thus combining AAS and 
stimulants will likely increase the risk for cardiac morbidity and sudden cardiac death also in 
young individuals. 
 
AAS used as a mean to rebuild a thin body. Psychoactive substance use prior to AAS 
initiation is common 60,61, and is also observed in our study. A less explored reason for this 
seems to be linked to the weight loss that often accompany the misuse of some substances, 
stimulants in particular 62. Four of the eleven AAS-using female and 44.5 % of the AAS-using 
male participants reported initiation of AAS because the use of psychoactive substances 
made them thinner. This is consistent with findings from a qualitative study describing how 
performance enchancing drugs were used during SUD-treatment to transform an emaciated 
drug user’s body to become more muscular and healthy looking 63. This, and our findings 
that 30.5 % of the AAS-group reported plans to use AAS in the future suggests that 
substance use as well as SUD-treatment may involve increased risk for AAS use. Conversely, 
AAS using recreational athletes may subsequently adopt psychoactive substance use. 
Motivations for such use may be associated with enhancing training or pain relief 64,65 
weight loss or fat burning 66. However, it is likely that psychoactive substance use is initiated 
or continued for recreational purposes or due to the development of SUD among 
recreational athletes. It is therefore important to note that AAS users are not a homogenous 
group, with significant variation in motivations for use, characteristics and potential health 
needs 4,5 and failure to recognize this has the potential to result in further barriers to 
effective engagement 67. 
 
The relatively lower prevalence of AAS use amongst women reflects the findings of 
community based research in Norway and globally 11,68. However, this may underestimate 
the levels of use as increased stigma and secrecy are associated with women’s use of these 
substances 69,70. Furthermore, as adverse consequences are more severe, often permanent 
and largely dose-dependent 13, the high AAS dosages reported among women in this study 
are a cause for concern. 
AAS use: a non-topic in SUD treatment. More than half of the study participants had not 
been asked about previous or present AAS use during treatment, suggesting that health 
professionals in SUD treatment facilities do not systematically identify and address AAS use. 
Furthermore, among those who had experienced that AAS was a topic during treatment, 
only 14.7% experienced their treatment providers to have expertise about AAS. Previous 
studies have found that AAS users perceive health professionals as unknowledgeable about 
AAS 71,72 and may avoid health services due to a fear of reporting practises resulting in 
sanctions 73 and stigmatization 74-76. In addition, use and possession of AAS during treatment 
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is reported to be a reason for expulsion from SUD-treatment 39 and information about 
current use may therefore not be revealed.  
4.1 Limitations  
Limitations of the study includes the use of self-report with a risk of underreporting AAS-
use, as some participants might be worried that their answers would leak to treatment 
providers or significant others. The study also has validity problems related to potential 
overestimation of use. Although all SUD-patients were informed that it was important to 
participate whether they had experience with AAS or not, it is possible that the survey 
theme «AAS use among patients in SUD-treatment» may have led some SUD-patients 
without AAS use experiences to refrain from participation. There are other sources of 
potential selection bias as well, e.g. language barriers, acute mental illness or being in a 
state of withdrawal that potentially might have hindered SUD-patients from participating. 
Furthermore, treatment facilities choosing not to participate in the study, may also be a 
potential selection bias. Also, reading difficulties, impaired memory and reduced 
concentration may have been a hindrance for responding to all parts of the questionnaire, 
or for participation in the study. As 80.5% of the participants were inpatients and most data 
collection occurred during the daytime, some patients could not participate as they had 
treatment appointments or were involved in other activities. In addition, it is possible that 
inpatients had more complex treatment needs than outpatients. Furthermore, one fourth of 
the participants were women with this being lower than the one third of SUD patients 
nationally.  
4.2 Conclusion 
While the use of AAS remains a minority activity within the general population, lifetime use 
of AAS amongst men and women in SUD treatment services in Norway is ten times as high. 
AAS use is associated with severe medical and psychological harms, and the comorbid use of 
AAS and psychoactive substances among SUD patients will increase the likelihood and 
severity of deleterious effects. There is a need to emphasize AAS use as an important part of 
SUD treatment, where the level of competence around AAS thematic among health 
professionals needs to be raised in order to address the needs of this patient group.  
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Figure 1  
Prevalence (%) of lifetime AAS use according to preferred substance among all men (n=406). Data is 
presented for the major drug categories, listed as the main drug of choice for more than 50 male 
participants.  
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Figure 2: AAS as an issue in SUD treatment 
 
The participants responded to the following questions: 
1. Have you been asked about AAS use during SUD-treatment? (n=547) 
2. Do you think use of AAS is important to take into account in SUD treatment? (n=547) 
3. Have you experienced your treatment providers to have knowledge about AAS? (n=186) 
When comparing the groups of SUD patients; no use (A), AAS use less than a year (B), AAS use from 1-3 years 
(C) and AAS use for more than 3 years (D) for three questions, group differences were found for question 1 
only: A ˂ B, C and D (p ˂ 0.0001), B ˂ D (P ˂ 0.021) 
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Table 1 Characteristics of male SUD patients with and without lifetime AAS use (n=401a)  
 
SUD non-AAS 
(n = 256) 
 SUD AAS 
(n = 145) 
 
 
 
 n (%) Range Missing n (%) Range Missing X2 p 
Demographics 
In a relationship 66 (27.0)  12 32 (23.7)  10 .35 .555 
Age (years), mean (SD) 39.8 (12.3) 19-71 2 33.1 (7.2) 20-51 2 -6.82 .000 
Completed High school 159 (66.8)  18 77 (55.4)  6 4.41 .036 
BMI, mean (SD) 26.8 (4.4) 16.7-42.9 9 26.7 (4.1) 17.8-46.3 4 -.26 .793 
 
Prescribed medication 
ADHD medications 42 (16.5)  1 44 (30.6)  1 9.98 .002 
TRT 6 (2.4)  1 10 (6.9)  1 3.92 .048 
OMT 41 (16.1)  1 43 (29.9)  1 9.71 .002 
 
Exercise habits 
Regular exercise 122 (49.8)  11 114 (81.4)  5 36.26 .000 
Workouts/week, mean (SD) 3.5 (1.4) 1-7 16 4.4 (1.8) 1-12 4 3.93 .000 
Regular strength training 77 (72.0)  15 107 (94.7)  1 19.12 .000 
 
aSix SUD patients who did not report whether they had used AAS or not, and seven gamblers were excluded 
from the analysis.  
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Table 2 Characteristics of substance use among male SUD non-AAS and lifetime AAS use 
SUD patients (n=401a) 
 
SUD non-AAS 
(n = 256) 
SUD AAS 
(n = 145) 
 
 
Substance use Mean (SD) Range Missing Mean (SD) Range Missing t p 
Debut age substance use  14.5 (3.4) 5-30 7 13.8 (2.6) 5-25 2 -2.26 .024 
Diagnosed with SUD (age)  31.4 (12.2) 13-69 38 24.3 (7.1) 12-44 18 -6.84 .000 
Yrs from debut-diagnose 17.0 (11.6) 1-53 39 10.7 (6.8) 1-29 18 -6.35 .000 
No. substances used/week 2.5 (1.8) 1-10 16 3.8 (2.0) 1-8 13 6.58 .000 
         
 n (%)   n (%)   X2  
Multiple substances/week 136 (56.2)  14 118 (86.8)  9 35.53 .000 
         
Preferred substance         
Alcohol 117 (46.1)  5 20 (14.0)  3 40.25 .000 
Stimulants* 34 (13.4)  5 43 (30.1)  3 15.24 .000 
BZD 10 (3.9)  5 10 (7.0)  3 1.20 .272 
Opioids** 25 (9.8)  5 23 (16.1)  3 2.79 .095 
Cannabis 30 (11.8)  5 24 (16.8)  3 1.52 .217 
Polysubstance 37 (14.6)  5 18 (12.6)  3 .16 .692 
Other 1 (0.4)  5 5 (3.5)  3 4.02 .045 
         
Substances used in a normal week        
Alcohol 169 (70.4)  16 75 (56.8)  13 6.39 .011 
Heroin 36 (15.0)  16 37 (28.0)  13 8.36 .004 
Methadone/subutex*** 40 (16.7)  16 39 (29.5)  13 7.69 .006 
Other opioids 23 (9.6)  16 29 (22.0)  13 9.86 .002 
BZD 89 (37.1)  16 90 (68.2)  13 31.76 .000 
Cocaine 29 (12.1)  16 40 (30.3)  13 17.53 .000 
Amphetamines 85 (35.4)  16 86 (65.2)  13 29.13 .000 
Cannabis 102 (42.5)  16 81 (61.4)  13 11.38 .001 
Other 24 (10.0)  16 28 (21.2)  13 8.00 .005 
a Six SUD patients who did not report whether they had used AAS or not, and seven gamblers were excluded 
from the analyses.  
*Amphetamines dominate among stimulants as preferred substance, only four in the SUD non-AAS group and 
two in the AAS group preferred cocaine.  
**Opioids as preferred substance for the SUD non-AAS group included 17 heroin, five unprescribed 
methadone/buprenorphine and three other opioids, and similar numbers for the AAS lifetime group was 15 
heroin, five unprescribed OMT-medication and three reported other opioids.  
*** Unprescribed use 
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Table 3 Characteristics of AAS usage among male SUD patients (n=145) 
  n (%) Range Missing 
Debut of age, mean (SD) 22.8 (6.1) 14-45 2 
Length of AAS use (months), mean (SD)  25.7 (39.0) 1-204 14 
Number of AAS combined, mean (SD) 2.4 (1.3) 0-9 25 
    
Average weekly AAS dose (mg) 
 <300 
 300-1000 
 >1000  
 
23 (19.7) 
66 (56.4) 
28 (23.9) 
 28 
    
Pattern of use 
Planned cycles 
Unplanned cycles 
Continuous use, variable dosages 
Continuous use, same dosage 
TRT 
Other 
 
43 (34.7) 
40 (32.3) 
5  (4.0) 
2  (1.6) 
2 (1.6) 
32 (25.8) 
 21 
Length cycle, weeks, mean (SD) 7 (4.9)  6 
Planning on using AAS in the future 45 (32.1)  5 
SUD prior to AAS debut 90 (64.3)  5 
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Table S1 Characteristics of substance use among male SUD non-AAS and lifetime AAS use 
SUD patients, excluding participants reporting alcohol as only preferred substance (n=334) 
 
SUD non-AAS 
(n = 189) 
SUD AAS 
(n = 145) 
 
 
Substance use Mean (SD) Range Missing Mean (SD) Range Missing t p 
Debut age substance use  14.2 (3.4) 5-30 4 13.8 (2.6) 5-25 2 -1.27 .204 
Diagnosed with SUD (age)  27.5 (9.2) 14-65 28 24.3 (7.1) 12-44 18 -3.36 .001 
Yrs from debut-diagnose 13.3 (9.0) 1-49 29 10.7 (6.8) 1-29 18 -2.82 .005 
No. substances used/week 3.0 (1.8) 1-10 10 3.8 (2.0) 1-8 13 3.71 .000 
         
 n (%)   n (%)   X2  
Multiple substances/week 136 (75.1)  8 118 (86.8)  9 5.88 .015 
         
Preferred substance         
Alcohol 50 (26.7)  2 20 (14.0)  2 7.14 .008 
Stimulants* 34 (18.2)  2 43 (30.1)  2 5.75 .016 
BZD 10 (5.3)  2 10 (7.0)  2 .15 .698 
Opioids** 25 (13.4)  2 23 (16.1)  2 .29 .592 
Cannabis 30 (16.0)  2 24 (16.8)  2 .00 .976 
Polysubstance 37 (19.8)  2 18 (12.6)  2 2.53 .112 
Other 1 (0.5)  2 5 (3.5)  2 2.50 .114 
         
Substances used in a normal week        
Alcohol 108 (60.3)  10 75 (56.8)  13 .26 .613 
Heroin 36 (20.1)  10 37 (28.0)  13 2.23 .135 
Methadone/subutex*** 40 (22.3)  10 39 (29.5)  13 1.72 .190 
Other opioids 23 (12.8)  10 29 (22.0)  13 3.91 .048 
BZD 89 (49.7)  10 90 (68.2)  13 9.86 .002 
Cocaine 29 (16.2)  10 40 (30.3)  13 7.95 .005 
Amphetamines 85 (47.5)  10 86 (65.2)  13 8.88 .003 
Cannabis 102 (57.0)  10 81 (61.4)  13 .43 .510 
Other 24 (13.4)  10 28 (21.2)  13 2.79 .095 
a 67 male patients who only used alcohol, six SUD patients who did not report whether they had used AAS or 
not, and seven gamblers were excluded from the analyses.  
*Amphetamines dominate among stimulants as preferred substance, only four in the SUD non-AAS group and 
two in the AAS group preferred cocaine.  
**Opioids as preferred substance for the SUD non-AAS group included 17 heroin, five unprescribed 
methadone/buprenorphine and three other opioids and similar numbers for the AAS lifetime group was 15 
heroin, five unprescribed OMT-medication and three reported other opioids.  
*** Unprescribed use 
 
 
 
